{"id":"sph3127-tablet-dose-1","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Unfortunately, there is limited information available about the mechanism of action of SPH3127 tablet Dose 1.","oneSentence":"SPH3127 tablet Dose 1 is a drug with an unknown mechanism of action.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:35:51.222Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05593575","phase":"PHASE2","title":"Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2023-03-22","conditions":"Diabetic Kidney Disease","enrollment":305},{"nctId":"NCT03128138","phase":"PHASE1","title":"Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2016-12-01","conditions":"Hypertension","enrollment":48},{"nctId":"NCT05359055","phase":"PHASE1, PHASE2","title":"Drug-drug Interaction Study of SPH3127","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2021-12-13","conditions":"Drug Drug Interaction","enrollment":40},{"nctId":"NCT03756103","phase":"PHASE2","title":"Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2019-01-11","conditions":"Hypertension,Essential","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["renion inhibitor","renion inhibitor placebo"],"phase":"phase_3","status":"active","brandName":"SPH3127 tablet Dose 1","genericName":"SPH3127 tablet Dose 1","companyName":"Shanghai Pharmaceuticals Holding Co., Ltd","companyId":"shanghai-pharmaceuticals-holding-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPH3127 is a small molecule renin inhibitor used in the treatment of Diabetic Kidney Disease and Hypertension. It is being studied in a Phase 2 clinical trial to evaluate its efficacy and safety in patients with Diabetic Kidney Disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}